Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 21, 2021- Median progression-free survival (PFS) of 7.6 months and disease control rate of 87.5% observed in conventional chondrosarcoma patients in Phase 1
-
May 13, 2021
-
Jan 13, 2021Registration-enabling study expected to begin dosing in the second or third quarter of this year
-
Nov 13, 2020- Successful completion of initial public offering with net proceeds of $126 million; cash and cash equivalents of $128 million as of September 30th